GlassScriptPhysician profile
Charlsie Woodard
NPI 1609198761
$2,131.03
in general payments reported to CMS, 2019-2025
21 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $310 · 2023: $878 · 2024: $334 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $612.52 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $279.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $207.95 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Abbvie INC. | $165.54 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $151.56 | 2023-2024 | Xarelto |
| Ferring Pharmaceuticals INC. | $125.00 | 2022 | |
| Melinta Therapeutics, LLC | $95.74 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Alexion Pharmaceuticals, INC. | $77.02 | 2021-2024 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.44 | 2021-2022 | |
| Pfizer INC. | $57.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.86 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $36.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.47 | 2024-2025 | Xifaxan |
| Argenx US, INC. | $27.32 | 2023 | Vyvgart |
| E.R. Squibb & Sons, L.L.C. | $27.30 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $25.11 | 2024 | Paradise Renal Denervation System |
| Stryker Corporation | $23.51 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insmed, INC. | $23.20 | 2025 | Arikayce |
| Janssen Biotech, INC. | $17.16 | 2023 | Darzalex, Imbruvica |
| Bioxcel Therapeutics, INC. | $14.96 | 2023 | Igalmi |
| Csl Behring | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlsie Woodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.